F8 and hemophilia A: A total of 86% of patients currently receiving prophylactic treatment with damoctocog alfa pegol had previously been treated in prophylaxis with other FVIII concentrates, while 14% had previously been treated exclusively on demand; of these, 57% were affected by moderate hemophilia A. Almost all patients (83%) in the previous prophylactic treatment used standard half-life recombinant FVIII concentrates, more precisely 50% octocog alfa (Kovaltry), and 33% different standard half-life products (another octocog alfa, turoctocog alfa, moroctocog alfa, rFVIII-single chain, rhFVIII).